Literature DB >> 24737634

Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States.

Gery P Guy1, Lisa C Richardson, Michael P Pignone, Marcus Plescia.   

Abstract

BACKGROUND: Despite clear recommendations and evidence linking colorectal cancer screening to lower incidence and mortality, > 40% of adults are not up to date with screening. Existing domestic and international models of organized cancer screening programs have been effective in increasing screening rates. Implementing an organized, evidence-based, national screening program may be an effective approach to increasing screening rates.
METHODS: In the current study, the authors estimated the initial investment required and the cost per person screened of a nationwide fecal immunochemical test (FIT)-based colorectal cancer screening program among adults aged 50 years to 75 years.
RESULTS: The initial additional investment required was estimated at $277.9 to $318.2 million annually, with an estimated 8.7 to 9.4 million individuals screened at a cost of $32 to $39 per person screened. The program was estimated to prevent 2900 to 3100 deaths annually.
CONCLUSIONS: The results of the current study indicate that implementing a national screening program would make a substantial public health impact at a moderate cost per person screened. Results from this analysis may provide useful information for understanding the public health benefit of an organized screening delivery system and the potential resources required to implement a nationwide colorectal cancer screening program, and help guide decisions about program planning, design, and implementation.
© 2014 American Cancer Society.

Entities:  

Keywords:  colorectal cancer; early detection; health economics; public health; screening

Mesh:

Year:  2014        PMID: 24737634      PMCID: PMC4593052          DOI: 10.1002/cncr.28724

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Optimizing colorectal cancer screening by getting FIT right.

Authors:  Theodore R Levin
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

2.  The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.

Authors:  Donatus U Ekwueme; Gery P Guy; Chunyu Li; Sun Hee Rim; Pratibha Parelkar; Suephy C Chen
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

Review 3.  Organized colorectal cancer screening in integrated health care systems.

Authors:  Theodore R Levin; Laura Jamieson; Daniel A Burley; Juan Reyes; Michael Oehrli; Cindy Caldwell
Journal:  Epidemiol Rev       Date:  2011-06-27       Impact factor: 6.222

4.  Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.

Authors:  D A Lieberman; D G Weiss; J H Bond; D J Ahnen; H Garewal; G Chejfec
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

5.  A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.

Authors:  Zohar Levi; Shlomo Birkenfeld; Alex Vilkin; Micha Bar-Chana; Irena Lifshitz; Miri Chared; Eran Maoz; Yaron Niv
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

6.  How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Authors:  Janneke A Wilschut; Ewout W Steyerberg; Monique E van Leerdam; Iris Lansdorp-Vogelaar; J Dik F Habbema; Marjolein van Ballegooijen
Journal:  Cancer       Date:  2011-03-08       Impact factor: 6.860

7.  Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test.

Authors:  Barbara Turner; Ronald E Myers; Terry Hyslop; Walter W Hauck; David Weinberg; Timothy Brigham; James Grana; Todd Rothermel; Neil Schlackman
Journal:  J Gen Intern Med       Date:  2003-05       Impact factor: 5.128

Review 8.  Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results.

Authors:  K Robin Yabroff; Kathleen Shakira Washington; Amy Leader; Elizabeth Neilson; Jeanne Mandelblatt
Journal:  Med Care Res Rev       Date:  2003-09       Impact factor: 3.929

9.  Impact of a physician-oriented intervention on follow-up in colorectal cancer screening.

Authors:  Ronald E Myers; Barbara Turner; David Weinberg; Terry Hyslop; Walter W Hauck; Timothy Brigham; Todd Rothermel; James Grana; Neil Schlackman
Journal:  Prev Med       Date:  2004-04       Impact factor: 4.018

Review 10.  Cost-effectiveness of colorectal cancer screening.

Authors:  Iris Lansdorp-Vogelaar; Amy B Knudsen; Hermann Brenner
Journal:  Epidemiol Rev       Date:  2011-06-01       Impact factor: 6.222

View more
  15 in total

Review 1.  Data-Powered Participatory Decision Making: Leveraging Systems Thinking and Simulation to Guide Selection and Implementation of Evidence-Based Colorectal Cancer Screening Interventions.

Authors:  Stephanie B Wheeler; Jennifer Leeman; Kristen Hassmiller Lich; Florence K L Tangka; Melinda M Davis; Lisa C Richardson
Journal:  Cancer J       Date:  2018 May/Jun       Impact factor: 3.360

2.  Outreach and Inreach Strategies for Colorectal Cancer Screening Among Latinos at a Federally Qualified Health Center: A Randomized Controlled Trial, 2015-2018.

Authors:  Sheila F Castañeda; Balambal Bharti; Marielena Rojas; Silvia Mercado; Adriana M Bearse; Jasmine Camacho; Manuel Song Lopez; Fatima Muñoz; Shawne O'Connell; Lin Liu; Gregory A Talavera; Samir Gupta
Journal:  Am J Public Health       Date:  2020-02-20       Impact factor: 9.308

3.  Understanding the processes that Federally Qualified Health Centers use to select and implement colorectal cancer screening interventions: a qualitative study.

Authors:  Jennifer Leeman; Natoshia Askelson; Linda K Ko; Catherine L Rohweder; Jade Avelis; Alicia Best; Daniela Friedman; Karen Glanz; Laura Seegmiller; Lindsay Stradtman; Robin C Vanderpool
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

4.  Editorial: Financial Incentives to Improve Colorectal Cancer Screening: Does it Make Cents?

Authors:  Jeffrey Adler; Jason A Dominitz
Journal:  Am J Gastroenterol       Date:  2016-11       Impact factor: 10.864

5.  Community-Based Colorectal Cancer Screening in a Rural Population: Who Returns Fecal Immunochemical Test (FIT) Kits?

Authors:  Richard A Crosby; Lindsay Stradtman; Tom Collins; Robin Vanderpool
Journal:  J Rural Health       Date:  2016-09-21       Impact factor: 4.333

6.  Effectiveness and Cost-effectiveness of Mailed FIT in a Safety Net Clinic Population.

Authors:  Michael Pignone; Brennan Lanier; Nicole Kluz; Victoria Valencia; Patrick Chang; Todd Olmstead
Journal:  J Gen Intern Med       Date:  2021-04-30       Impact factor: 5.128

7.  Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.

Authors:  Samir Gupta; Gloria D Coronado; Keith Argenbright; Alison T Brenner; Sheila F Castañeda; Jason A Dominitz; Beverly Green; Rachel B Issaka; Theodore R Levin; Daniel S Reuland; Lisa C Richardson; Douglas J Robertson; Amit G Singal; Michael Pignone
Journal:  CA Cancer J Clin       Date:  2020-06-25       Impact factor: 286.130

8.  The Utility of Endoscopic Biopsies in Patients with Normal Upper Endoscopy.

Authors:  Anouar Teriaky; Abdullah AlNasser; Carolyn McLean; James Gregor; Brian Yan
Journal:  Can J Gastroenterol Hepatol       Date:  2016-07-10

9.  Modeling and Control of Colorectal Cancer.

Authors:  Li-Peng Song; Hao-Yu Wang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

10.  Startup and implementation costs of a colorectal cancer screening tailored navigation research study.

Authors:  Julie Bucho-Gonzalez; Patricia M Herman; Linda Larkey; Usha Menon; Laura Szalacha
Journal:  Eval Program Plann       Date:  2021-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.